Research programme: human therapeutic antibodies - Medarex/Pfizer

Drug Profile

Research programme: human therapeutic antibodies - Medarex/Pfizer

Latest Information Update: 03 Sep 2009

Price : $50

At a glance

  • Originator Medarex; Pfizer
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Autoimmune disorders; Bacterial infections; Cancer; Inflammation; Viral infections

Most Recent Events

  • 02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb
  • 08 Sep 2008 Pfizer files an IND application with the US FDA for an undisclosed indication
  • 13 Mar 2008 This collaborative programme is still active
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top